These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
735 related articles for article (PubMed ID: 23328811)
1. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Lalezari S; Chou AP; Tran A; Solis OE; Khanlou N; Chen W; Li S; Carrillo JA; Chowdhury R; Selfridge J; Sanchez DE; Wilson RW; Zurayk M; Lalezari J; Lou JJ; Ormiston L; Ancheta K; Hanna R; Miller P; Piccioni D; Ellingson BM; Buchanan C; Mischel PS; Nghiemphu PL; Green R; Wang HJ; Pope WB; Liau LM; Elashoff RM; Cloughesy TF; Yong WH; Lai A Neuro Oncol; 2013 Mar; 15(3):370-81. PubMed ID: 23328811 [TBL] [Abstract][Full Text] [Related]
2. Correlation between O6-methylguanine-DNA methyltransferase and survival in elderly patients with glioblastoma treated with radiotherapy plus concomitant and adjuvant temozolomide. Minniti G; Salvati M; Arcella A; Buttarelli F; D'Elia A; Lanzetta G; Esposito V; Scarpino S; Maurizi Enrici R; Giangaspero F J Neurooncol; 2011 Apr; 102(2):311-6. PubMed ID: 20686820 [TBL] [Abstract][Full Text] [Related]
3. MGMT gene promoter methylation as a potent prognostic factor in glioblastoma treated with temozolomide-based chemoradiotherapy: a single-institution study. Kim YS; Kim SH; Cho J; Kim JW; Chang JH; Kim DS; Lee KS; Suh CO Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):661-7. PubMed ID: 22414280 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide. McAleenan A; Kelly C; Spiga F; Kernohan A; Cheng HY; Dawson S; Schmidt L; Robinson T; Brandner S; Faulkner CL; Wragg C; Jefferies S; Howell A; Vale L; Higgins JPT; Kurian KM Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013316. PubMed ID: 33710615 [TBL] [Abstract][Full Text] [Related]
5. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay? Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H J Neurosurg; 2019 Mar; 130(3):780-788. PubMed ID: 29726772 [TBL] [Abstract][Full Text] [Related]
6. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas. Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398 [TBL] [Abstract][Full Text] [Related]
7. Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma. Kristensen LS; Michaelsen SR; Dyrbye H; Aslan D; Grunnet K; Christensen IJ; Poulsen HS; Grønbæk K; Broholm H J Neuropathol Exp Neurol; 2016 Mar; 75(3):246-55. PubMed ID: 26883115 [TBL] [Abstract][Full Text] [Related]
8. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646 [TBL] [Abstract][Full Text] [Related]
9. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma. Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829 [TBL] [Abstract][Full Text] [Related]
10. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma. Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970 [TBL] [Abstract][Full Text] [Related]
11. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952 [TBL] [Abstract][Full Text] [Related]
12. Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival. Schaff LR; Yan D; Thyparambil S; Tian Y; Cecchi F; Rosenblum M; Reiner AS; Panageas KS; Hembrough T; Lin AL J Neurooncol; 2020 Jan; 146(1):163-170. PubMed ID: 31823165 [TBL] [Abstract][Full Text] [Related]
13. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
14. Clinical correlation of MGMT protein expression and promoter methylation in Chinese glioblastoma patients. Tang K; Jin Q; Yan W; Zhang W; You G; Liu Y; Jiang T Med Oncol; 2012 Jun; 29(2):1292-6. PubMed ID: 21394635 [TBL] [Abstract][Full Text] [Related]
15. Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. Jung TY; Jung S; Moon KS; Kim IY; Kang SS; Kim YH; Park CS; Lee KH Oncol Rep; 2010 May; 23(5):1269-76. PubMed ID: 20372840 [TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes of concomitant chemoradiotherapy with temozolomide for newly diagnosed glioblastoma patients: A single-center analysis. Roh TH; Park HH; Kang SG; Moon JH; Kim EH; Hong CK; Ahn SS; Choi HJ; Cho J; Kim SH; Lee SK; Kim DS; Kim SH; Suh CO; Lee KS; Chang JH Medicine (Baltimore); 2017 Jul; 96(27):e7422. PubMed ID: 28682902 [TBL] [Abstract][Full Text] [Related]
18. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients. Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344 [TBL] [Abstract][Full Text] [Related]
19. IDH mutation and MGMT promoter methylation in glioblastoma: results of a prospective registry. Yang P; Zhang W; Wang Y; Peng X; Chen B; Qiu X; Li G; Li S; Wu C; Yao K; Li W; Yan W; Li J; You Y; Chen CC; Jiang T Oncotarget; 2015 Dec; 6(38):40896-906. PubMed ID: 26503470 [TBL] [Abstract][Full Text] [Related]
20. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. Christians A; Hartmann C; Benner A; Meyer J; von Deimling A; Weller M; Wick W; Weiler M PLoS One; 2012; 7(3):e33449. PubMed ID: 22428052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]